Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
GlaxoSmithKline Australia
Administration route
Intramuscular injection
Vaccine group
Meningococcal B vaccine
Description:
Registered for use in people aged ≥2 months.
MenB-MC — recombinant multicomponent meningococcal serogroup B vaccine
Each 0.5 mL monodose pre-filled syringe contains:
- 50 µg Neisseria meningitidis serogroup B Neisseria heparin binding antigen fusion protein
- 50 µg Neisseria meningitidis serogroup B Neisseria adhesion A protein
- 50 µg Neisseria meningitidis serogroup B factor H binding protein fusion protein
- 25 µg outer membrane vesicles from Neisseria meningitidis serogroup B strain NZ98/254 (measured as amount of total protein containing the PorA P1.4)
Adsorbed onto 0.5 mg aluminium hydroxide.
For Product Information and Consumer Medicine Information about Bexsero visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases